AbstractObjectives. The purpose of this study was to assess the efficacy of 150 mg of aspirin plus 100 mg of alteplase, administered as two intravenous bolus injections of 50 mg each given 30 min apart, and followed by intravenous heparin, on infarct-related coronary artery patency (Thrombolysis in Myocardial Infarction [TIMI] flow grade 3).Background. previous workers have shown in animals that reducing the duration of an infusion of recombinant tissue-type plasminogen activator increases the initial rate of thrombolysis, resulting in high early infarct-related coronary artery patenecy rates. The logical progression of this idea is bolus administration.Methods, Consecutive patients presenting up to 6 h from the onset of symptoms were recru...
BACKGROUND: Lanoteplase (nPA) is a rationally designed variant of tissue plasminogen activator with ...
AbstractPharmacokinetics and fibrin specificity of alteplase (recombinant tissue-type plasminogen ac...
To assess the efficacy of intravenous streptokinase in patients with acute myocardial infarction, 40...
AbstractObjectives. The purpose of this study was to assess the efficacy of 150 mg of aspirin plus 1...
AbstractClot dissolution with restoration of infarct-related artery blood flow is the likely mechani...
Background : This study was performed to compare double bolus urokinase (UK) regimen with front-load...
AbstractObjectives. This double-blind, randomized, multicenler trial was designed to compare the eff...
It has been previously shown that double-bolus reteplase (r-PA) resulted in superior TIMI 3 flow rat...
BACKGROUND. The European Cooperative Study Group conducted two randomized trials in patients with su...
Tissue type plasminogen activator is available, through recombinant technology, for thrombolytic use...
AbstractObjectives. Our aim was to design and evaluate a new and easily administered recombinant tis...
AbstractObjectives. The Liquemin in Myocardial Infarction During Thrombolysis With Saruplase (LIMITS...
AbstractTo determine whether a weight-adjusted high dose (2 mg/kg body weight over 3 h) rapid infusi...
The beneficial effect of aspirin (ASA) in unstable angina is well established, yet data on effect of...
OBJECTIVES: Most randomised trials of anticoagulant therapy for suspected acute myocardial infarctio...
BACKGROUND: Lanoteplase (nPA) is a rationally designed variant of tissue plasminogen activator with ...
AbstractPharmacokinetics and fibrin specificity of alteplase (recombinant tissue-type plasminogen ac...
To assess the efficacy of intravenous streptokinase in patients with acute myocardial infarction, 40...
AbstractObjectives. The purpose of this study was to assess the efficacy of 150 mg of aspirin plus 1...
AbstractClot dissolution with restoration of infarct-related artery blood flow is the likely mechani...
Background : This study was performed to compare double bolus urokinase (UK) regimen with front-load...
AbstractObjectives. This double-blind, randomized, multicenler trial was designed to compare the eff...
It has been previously shown that double-bolus reteplase (r-PA) resulted in superior TIMI 3 flow rat...
BACKGROUND. The European Cooperative Study Group conducted two randomized trials in patients with su...
Tissue type plasminogen activator is available, through recombinant technology, for thrombolytic use...
AbstractObjectives. Our aim was to design and evaluate a new and easily administered recombinant tis...
AbstractObjectives. The Liquemin in Myocardial Infarction During Thrombolysis With Saruplase (LIMITS...
AbstractTo determine whether a weight-adjusted high dose (2 mg/kg body weight over 3 h) rapid infusi...
The beneficial effect of aspirin (ASA) in unstable angina is well established, yet data on effect of...
OBJECTIVES: Most randomised trials of anticoagulant therapy for suspected acute myocardial infarctio...
BACKGROUND: Lanoteplase (nPA) is a rationally designed variant of tissue plasminogen activator with ...
AbstractPharmacokinetics and fibrin specificity of alteplase (recombinant tissue-type plasminogen ac...
To assess the efficacy of intravenous streptokinase in patients with acute myocardial infarction, 40...